D-BSSE startup BioVersys becomes a Swiss listed company
On 29 January, BioVersys launches its Initial Public Offering on the SIX Swiss Exchange. “Today marks the first step of us engaging with the public so that we may make the next clinical phase of developing BV100 and alpibectir and their eventual approval a reality,” says Marc Gitzinger, CEO and Co-Founder of BioVersys. BV100 and alpibectir are novel antimicrobial drug candidates targeting the most drug-resistant bacterial pathogens Acinetobacter baumannii and Mycobacterium tuberculosis.
BioVersys AG, a multi-asset, clinical-stage biopharmaceutical company domiciled in Basel which focusses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant bacteria. The 2008-founded ETH spinoff originates from the Biotechnology Lab of Martin Fussenegger.
Find external page media release on the BioVersys website; media release on the external page website of SIX.
Learn about all startup companies originating from D-BSSE labs.